| Literature DB >> 33447426 |
Jingjing Xu1, Zhong Qin1, Yanjuan Wang1, Chunxiao Hu1, Guilong Wang1, Zhengfeng Gu1, Shengjie Yuan1, Jingyu Chen2,3, Dongxiao Huang1, Zhiping Wang1,4.
Abstract
BACKGROUND: Lactic acidosis is often seen in lung transplantation (LTx). Postoperative lactate is frequently associated with poor outcome in postoperative and critically ill patients. Our aim was to evaluate the predictive value of postoperative peak lactate levels within 72 h of LTx for 30-day and late mortality.Entities:
Keywords: Hyperlactatemia; lung transplantation (LTx); mortality; outcome
Year: 2020 PMID: 33447426 PMCID: PMC7797848 DOI: 10.21037/jtd-20-3445
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Figure 1A flowchart of patient inclusion and exclusion.
Clinical and preoperative characteristics of patients (n=255)
| Variable | Group 1 (PL <5 mmol/L) (n=153) | Group 2 (PL 5–10 mmol/L) (n=86) | Group 3 (PL >10 mmol/L) (n=16) | Total (n=255) |
|---|---|---|---|---|
| Male | 124 (81.05) | 67 (77.91) | 13 (81.25) | 204 (80.0) |
| Female | 29 (18.95) | 19 (22.09) | 3 (18.75) | 51 (20.0) |
| Age (years) | 55.93±12.10 | 56.13±11.81 | 49.68±13.82 | 55.61±12.16 |
| Lac | 3.23±1.02 | 6.53±1.32 | 13.49±1.78 | 4.99±2.93 |
| BE | 6.86±3.65 | 6.34±3.12 | 8.62±5.61 | 6.80±3.66 |
| HBP | 20 (13.07) | 15 (17.44) | 0 | 35 (13.73) |
| Diabetes | 24 (15.69) | 12 (13.95) | 0 | 36 (14.12) |
| CHD | 13 (8.50) | 4 (4.65) | 2 (12.5) | 19 (7.45) |
| ECMO support | 82 (53.59) | 53 (61.63) | 10 (62.5) | 145 (56.86) |
| PAP | 22 (14.1) | 17 (19.77) | 1 (6.25) | 40 (15.69) |
| Bilateral lung | 68 (44.44) | 38 (44.19) | 3 (18.75) | 109 (42.75) |
The data are shown as mean ± standard deviation or n (%). PL, peak arterial lactate level; LAC, lactate; BE, base excess; COPD, chronic obstructive pulmonary disease; HBP, hypertension; CHD, coronary heart disease; ECMO, extracorporeal membrane oxygenation; PAP, pulmonary artery pressure.
Distribution of underlying lung disease in patients
| Underlying lung disease | Group 1 (n=153) | Group 2 (n=86) | Group 3 (n=16) | Total (n=255) |
|---|---|---|---|---|
| Pulmonary fibrosis | 75 (49.02) | 38 (44.19) | 7 (43.75) | 128 (50.20) |
| COPD | 31 (20.26) | 12 (13.95) | 2 (12.5) | 45 (17.65) |
| Interstitial lung diseases | 15 (9.80) | 12 (13.95) | 1 (6.25) | 28 (10.98) |
| Bronchiectasis | 9 (5.88) | 7 (8.14) | 1 (6.25) | 17 (6.67) |
| Silicosis | 8 (5.23) | 9 (10.47) | 3 (18.75) | 20 (7.84) |
| Others | 13 (8.50) | 7 (8.14) | 1 (6.25) | 21 (8.24) |
The data are shown as n (%). COPD, chronic obstructive pulmonary disease.
30-day mortality in the three groups
| Variable | Group 1 (n=153) | Group 2 (n=86) | Group 3 (n=16) | Total (n=255) | P value |
|---|---|---|---|---|---|
| Early mortality | 26 (16.99) | 22 (25.58) | 11 (68.8) | 59 (23.14) | <0.01 |
The data are shown as n (%).
Logistic regression analysis for predictors of 30-day mortality
| Risk factors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| PL | 2.34 (1.29–4.22) | 0.005 | 2.62 (1.42–4.84) | 0.002 | |
| Gender (male) | 0.75 (0.37–1.50) | 0.42 | – | – | |
| Age | 0.75 (0.42–1.35) | 0.34 | – | – | |
| ECMO | 0.68 (0.37–1.24) | 0.20 | – | – | |
| PH | 0.64 (0.27–1.53) | 0.32 | – | – | |
| Single/bilateral | 0.79 (0.44–1.41) | 0.42 | – | – | |
| BE | 0.83 (0.46–1.49) | 0.52 | – | – | |
| HBP | 0.39 (0.13–1.15) | 0.09 | 0.87 (0.38–1.06) | 0.076 | |
| Diabetes | 2.24 (1.05–4.77) | 0.04 | 2.60 (1.22–5.54) | 0.005 | |
| CHD | 1.20 (0.42–3.49) | 0.73 | – | – | |
PL, peak arterial lactate level; ECMO, extracorporeal membrane oxygenation; PH, pulmonary hypertension; BE, base excess; HBP, hypertension; CHD, coronary heart disease.
COX regression analysis for predictors of late mortality
| Risk factors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| PL | 2.60 (1.09–6.17) | 0.03 | 2.70 (1.13–6.42) | 0.025 | |
| Gender (male) | 1.40 (0.41–4.75) | 0.59 | – | – | |
| Age | 1.27 (0.53–3.07) | 0.60 | – | – | |
| ECMO | 0.53 (0.21–1.31) | 0.17 | – | – | |
| PA | 0.53 (0.12–2.28) | 0.39 | – | – | |
| Single/bilateral | 0.95 (0.40–2.29) | 0.92 | – | – | |
| BE | 0.29 (0.12–1.30) | 0.062 | – | – | |
| HBP | 1.09 (0.37–3.24) | 0.88 | – | – | |
| Diabetes | 2.76 (1.01–7.55) | 0.05 | 2.95 (1.07–8.10) | 0.036 | |
| CHD | 1.65 (0.38–7.10) | 0.50 | – | – | |
PL, peak arterial lactate level; ECMO, extracorporeal membrane oxygenation; PA, pulmonary hypertension; BE, base excess; HBP, hypertension; CHD, coronary heart disease.
Figure 2The distribution of peak lactate values of admitted patients, showing 40% had hyperlactatemia after LTx. LTx, lung transplantation.
Figure 3The Kaplan-Meier curves for the three groups showing postoperative survival stratified by PL in LTx patients (Log Rank P=0.000). PL, peak arterial lactate level; LTx, lung transplantation.
Figure 4The corrected survival curves for late survival in the three groups. All variables were entered in the Cox regression analysis (P=0.031).